King's College London BHF Centre, The Rayne Institute, St Thomas' Hospital, London, UK.
Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
Eur Heart J Acute Cardiovasc Care. 2022 Jun 7;11(4):325-335. doi: 10.1093/ehjacc/zuac007.
AIMS: Cardiac myosin-binding protein C (cMyC) demonstrated high diagnostic accuracy for the early detection of non-ST-elevation myocardial infarction (NSTEMI). Its dynamic release kinetics may enable a 0/1h-decision algorithm that is even more effective than the ESC hs-cTnT/I 0/1 h rule-in/rule-out algorithm. METHODS AND RESULTS: In a prospective international diagnostic study enrolling patients presenting with suspected NSTEMI to the emergency department, cMyC was measured at presentation and after 1 h in a blinded fashion. Modelled on the ESC hs-cTnT/I 0/1h-algorithms, we derived a 0/1h-cMyC-algorithm. Final diagnosis of NSTEMI was centrally adjudicated according to the 4th Universal Definition of Myocardial Infarction. Among 1495 patients, the prevalence of NSTEMI was 17%. The optimal derived 0/1h-algorithm ruled-out NSTEMI with cMyC 0 h concentration below 10 ng/L (irrespective of chest pain onset) or 0 h cMyC concentrations below 18 ng/L and 0/1 h increase <4 ng/L. Rule-in occurred with 0 h cMyC concentrations of at least 140 ng/L or 0/1 h increase ≥15 ng/L. In the validation cohort (n = 663), the 0/1h-cMyC-algorithm classified 347 patients (52.3%) as 'rule-out', 122 (18.4%) as 'rule-in', and 194 (29.3%) as 'observe'. Negative predictive value for NSTEMI was 99.6% [95% confidence interval (CI) 98.9-100%]; positive predictive value 71.1% (95% CI 63.1-79%). Direct comparison with the ESC hs-cTnT/I 0/1h-algorithms demonstrated comparable safety and even higher triage efficacy using the 0h-sample alone (48.1% vs. 21.2% for ESC hs-cTnT-0/1 h and 29.9% for ESC hs-cTnI-0/1 h; P < 0.001). CONCLUSION: The cMyC 0/1h-algorithm provided excellent safety and identified a greater proportion of patients suitable for direct rule-out or rule-in based on a single measurement than the ESC 0/1h-algorithm using hs-cTnT/I. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00470587.
目的:心肌肌球蛋白结合蛋白 C(cMyC)对非 ST 段抬高型心肌梗死(NSTEMI)的早期检测具有较高的诊断准确性。其动态释放动力学可能使 0/1h 决策算法比 ESC hs-cTnT/I 0/1h 规则内/规则外算法更有效。
方法和结果:在一项前瞻性国际诊断研究中,将疑似 NSTEMI 的患者收入急诊,以盲法在就诊时和 1 小时后测量 cMyC。根据 ESC hs-cTnT/I 0/1h 算法,我们推导出 0/1h-cMyC 算法。根据第 4 次心肌梗死通用定义,对 NSTEMI 的最终诊断进行中心裁定。在 1495 例患者中,NSTEMI 的患病率为 17%。最佳衍生的 0/1h 算法排除了 cMyC 0h 浓度低于 10ng/L(无论胸痛发作时间如何)或 0h cMyC 浓度低于 18ng/L 且 0/1h 增加<4ng/L 的 NSTEMI。规则纳入标准为 0h cMyC 浓度至少 140ng/L 或 0/1h 增加≥15ng/L。在验证队列(n=663)中,0/1h-cMyC 算法将 347 例患者(52.3%)归类为“排除”,122 例(18.4%)归类为“纳入”,194 例(29.3%)归类为“观察”。NSTEMI 的阴性预测值为 99.6%[95%置信区间(CI)98.9-100%];阳性预测值为 71.1%(95%CI 63.1-79%)。与 ESC hs-cTnT/I 0/1h 算法的直接比较表明,单独使用 0h 样本时,安全性相当,分诊效果更高(ESC hs-cTnT-0/1h 为 48.1%,ESC hs-cTnI-0/1h 为 29.9%,P<0.001)。
结论:cMyC 0/1h 算法提供了极好的安全性,并确定了更大比例的患者适合基于单次测量直接排除或纳入,优于使用 hs-cTnT/I 的 ESC 0/1h 算法。
试验注册:ClinicalTrials.gov 编号,NCT00470587。
Eur Heart J Acute Cardiovasc Care. 2022-6-7
Circulation. 2021-9-7
Eur Heart J Acute Cardiovasc Care. 2022-3-16
J Am Coll Cardiol. 2018-8-7
Circulation. 2017-11-3
Eur Heart J Acute Cardiovasc Care. 2023-10-25
J Mol Cell Cardiol Plus. 2022-9
J Am Heart Assoc. 2019-8-6
Clin Chem. 2019-1-9
Int J Cardiol. 2018-12-3
J Am Coll Cardiol. 2018-10-30
J Am Coll Cardiol. 2018-8-7
Eur Heart J Acute Cardiovasc Care. 2017-12-4